Saturday 17 October 2026 Export BTCY’s income statement to Excel — free account

Biotricity Inc.

Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

0.05 0.00 0.00%

Follow BTCY

Alert me

Market cap: $10.9M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 5/9
Altman Z: −33.34
Beneish M: −3.24
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 87.75%

Capital & Financial Ratios $m

Market Cap 10.87

Revenue 16.40

Net Income (2.69)

Free Cash Flow 0.16

Net Debt 26.21

Current Ratio 0.15

Debt/Equity (0.75)

P/E ratio 0.00

Fwd P/E 0.00

P/S ratio 0.07

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 31.42%

Next Y EPS Growth 72.26%

Next Y revenue growth 14.57%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.52%

10-year low 10-year high

EV/Sales against its own 10 years 0.52%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	1	0	0	0
Receivables	1	2	3	2
Inventory	2	2	1	1
Other	0	1	1	1
	4	5	6	6

	2024	2025	2026	Q'26
Payables	10	8	9	9
ST’ Debt	12	12	26	26
Other	1	0	2	2
	23	21	37	37

Compound Annual Growth %

	10y	5y	3y
Sales	—	36.43%	18.40%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	4	—	—	—	—
’26	4	4	4	4	16
’25	3	3	4	4	14
’24	3	3	3	3	12
’23	2	2	2	3	10
’22	2	2	2	2	8
’21	0	1	1	1	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	1	—	—	—	—
’26	0	0	(1)	0	(1)
’25	(1)	0	0	0	(2)
’24	(2)	(2)	(1)	(1)	(7)
’23	(4)	(4)	(3)	(2)	(14)
’22	(3)	(3)	(4)	(5)	(15)
’21	(2)	(2)	(3)	(4)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	1	—	—	—	—
’26	0	0	(1)	0	(1)
’25	(1)	0	0	0	(2)
’24	(2)	(2)	(1)	(1)	(7)
’23	(4)	(4)	(3)	(2)	(14)
’22	(3)	(3)	(5)	(5)	(15)
’21	(2)	(2)	(3)	(4)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.05)	—	—	—	—
’26	(0.03)	(0.03)	(0.04)	(0.02)	(0.11)
’25	(0.49)	(0.07)	(0.05)	(0.06)	(0.55)
’24	(0.39)	(0.44)	(0.34)	(0.47)	(1.66)
’23	(0.09)	(0.54)	(0.54)	(0.54)	(2.28)
’22	(0.90)	(1.56)	(0.90)	(0.72)	(4.02)
’21	(0.54)	(0.48)	(0.66)	(0.90)	(2.64)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	10.86	2.53	1.56	3.18	4.38	2.66	0.70	0.19	0.23	0.04	Analyst estimates 2027–2029 Powerpack
	High	117.00	48.90	13.50	13.26	31.80	24.60	5.82	1.67	0.83	0.33
People
People	Employees	—	—	—	—	—	—	—	—	46	46
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.30	0.35
Income, $m
Income, $m	Revenue	—	—	0	1	3	8	10	12	14	16
	Gross margin, %	—	—	15.04	34.27	37.60	59.74	56.46	69.27	76.61	80.94
	EBT	(8)	(9)	(9)	(11)	(15)	(29)	(19)	(14)	(8)	(2)
	EBT margin, %	0.00	0.00	(2,157.73)	(780.62)	(457.67)	(380.78)	(193.57)	(116.84)	(61.07)	(15.03)
	Net income	(8)	(9)	(9)	(11)	(15)	(29)	(19)	(14)	(8)	(2)
	Depreciation	1	1	—	0	2	9	1	2	2	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.07	0.24	0.54	1.01	1.11	1.34	0.64	0.59
	Earnings	(1.74)	(1.80)	(1.52)	(1.84)	(2.64)	(4.02)	(2.28)	(1.66)	(0.55)	(0.11)
	Cash flow	(0.87)	(0.97)	(0.94)	(1.31)	(1.77)	(2.00)	(1.56)	(0.74)	(0.11)	(0.03)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.87)	(0.97)	(0.94)	(1.31)	(1.77)	(2.01)	(1.56)	(0.74)	(0.11)	(0.03)
	Book value	(1.02)	0.03	(0.32)	(0.50)	(1.09)	(0.28)	(2.29)	(3.50)	(1.49)	(1.27)
	Shares, m	4	5	6	6	6	8	9	9	22	27
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	76.29	24.69	26.56	13.49	2.51	1.07	0.53	0.41
	P/B	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	—	—	78.39	25.50	27.28	13.74	4.30	2.87	2.33	2.07
	EV/FCF	—	—	(3.09)	(4.60)	(8.33)	(6.92)	(3.05)	(5.14)	(13.33)	(44.16)
Cash, $m
Cash, $m	Operating cash flow	(4)	(5)	(5)	(8)	(11)	(15)	(14)	(7)	(2)	(1)
	Capex	—	—	—	—	—	0	—	—	—	—
	Free cash flow	(4)	(5)	(5)	(8)	(11)	(15)	(14)	(7)	(2)	(1)
Balance, $m
Balance, $m	Working capital	(4)	0	(2)	(2)	(6)	10	(6)	(18)	(16)	(31)
	Total debt	2	—	1	2	5	14	18	22	25	27
	Net debt	1	(1)	1	1	2	2	17	22	25	27
	Shareholders’ equity	(4)	0	(2)	(3)	(7)	(2)	(20)	(31)	(32)	(35)
Returns, %
Returns, %	ROA	(2,886.99)	(1,229.41)	(1,210.07)	(907.77)	(510.78)	(286.22)	(168.48)	(239.76)	(206.19)	(51.76)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	184.76	409.52	1,071.00	474.03	334.63	673.20	177.66	58.19	37.62	9.38

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 28 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IRIX IRIDEX Corporation	$14.5M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%
CTSO Cytosorbents Corporation	$9.7M	— (loss-making)	— (loss-making)	+0.17% (above 0%: growing)	n/m	+64.90% (above 0%: growing)	73.18%	(27.39%)	Compare
NMTC NeuroOne Medical Technologies Corporation	$9.5M	— (loss-making)	— (loss-making)	+16.33% (above 0%: growing)	n/m	+26.91% (above 0%: growing)	59.94%	(122.87%)	Compare
BMRA Biomerica, Inc.	$8.6M	— (loss-making)	11.4×	+16.96% (above 0%: growing)	n/m	−35.05% (below 0%: shrinking)	(7.88%)	(174.77%)	Compare
AEMD Aethlon Medical, Inc.	$8.5M	— (loss-making)	— (loss-making)	+335.00% (above 0%: growing)	n/m	−11.13% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$11.3M	—	—	+16.33%	—	+33.52%	47.07%	(75.13%)

All 149 Medical Devices stocks →

Biotricity Inc. (BTCY) key facts

Strength: Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025.
Biotricity Inc. (BTCY) is a Medical Devices company in the Healthcare sector.
As of October 16, 2026, BTCY traded at $0.05, a market capitalization of $10.9 million.
Return on equity was 9.38% and debt-to-equity -0.75.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −33.34 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.